Get started
Author

Allan Buzibye

Observed names: A. Buzibye, Allan Kengo, Buzibye Allan, Buzibye, Allan
ORCID: 0000-0001-5874-3219
Observed ORCID: 0000-0001-5874-3219
OpenAlex ID: A5083300418
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
2015 · Kimberly K. Scarsi, Kristin M. Darin, et al. · Clinical Infectious Diseases · 88
PDF
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial
2021 · Fiona V Cresswell, David B Meya, et al. · Clinical Infectious Diseases · 76
Oral pre‐exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study
2022 · Yunia Mayanja, Onesmus Kamacooko, et al. · Journal of the International AIDS Society · 57
PDF
Delayed Sputum Culture Conversion in Tuberculosis–Human Immunodeficiency Virus–Coinfected Patients With Low Isoniazid and Rifampicin Concentrations
2018 · Christine Sekaggya-Wiltshire, Amrei von Braun, et al. · Clinical Infectious Diseases · 53
Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?
2019 · Christine Sekaggya-Wiltshire, Maxwell Chirehwa, et al. · Antimicrobial Agents and Chemotherapy · 51
PDF
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients
2016 · C. Sekaggya-Wiltshire, A. von Braun, et al. · Journal of Antimicrobial Chemotherapy · 38
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin
2022 · Christine Sekaggya-Wiltshire, Ruth Nabisere, et al. · Clinical Infectious Diseases · 24
PDF
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
2023 · Frank Mulindwa, Barbara Castelnuovo, et al. · AIDS Research and Therapy · 20
PDF
Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda
2023 · Moses Ocan, Loyce Nakalembe, et al. · Malaria Journal · 18
PDF
Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique
2014 · Mohammed Lamorde, Quirine Fillekes, et al. · BMC Infectious Diseases · 13
PDF
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin
2023 · Allan Kengo, Ruth Nabisere, et al. · Antimicrobial Agents and Chemotherapy · 11
PDF
Pharmacokinetics of antimalarial drugs used to treat uncomplicated malaria in breastfeeding mother-infant pairs: An observational pharmacokinetic study
2023 · Ritah Nakijoba, Aida Nakayiwa Kawuma, et al. · Wellcome Open Research · 11
Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study
2019 · Allan Buzibye, Joseph Musaazi, et al. · AIDS Research and Therapy · 11
PDF
High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment
2018 · Amrei von Braun, Barbara Castelnuovo, et al. · Journal of Antimicrobial Chemotherapy · 10
PDF
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study
2017 · Christine Sekaggya-Wiltshire, Barbara Castelnuovo, et al. · BMJ Open · 10
PDF
Antiretroviral drugs found in pork on Ugandan market: Implications for HIV/AIDS treatment
2020 · Ritah Nakato, James K. Tumwine, et al. · One Health · 9
PDF
Low isoniazid and rifampicin concentrations in TB/HIV co‐infected patients in Uganda
2014 · Christine Sekaggya Wiltshire, Mohammed Lamorde, et al. · Journal of the International AIDS Society · 9
PDF
A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda
2025 · Eva Agnes Laker Odongpiny, Melanie Nicol, et al. · HIV Medicine · 7
PDF
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
2023 · Frank Mulindwa, Barbara Castelnuovo, et al. · AIDS Research and Therapy · 6
PDF
Dolutegravir-associated hyperglycemia: a narrative review
2025 · Allan Buzibye, Barbara Castelnuovo, et al. · AIDS Research and Therapy · 5
PDF
Pharmacokinetics of drugs used to treat drug sensitive-tuberculosis in breastfeeding mother-infant pairs: An observational pharmacokinetic study
2023 · Ritah Nakijoba, Aida Nakayiwa Kawuma, et al. · Wellcome Open Research · 5
Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs
2024 · Aida N. Kawuma, Francis Williams Ojara, et al. · CPT Pharmacometrics & Systems Pharmacology · 3
PDF
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin
2023 · Allan Kengo, Kamunkhwala Gausi, et al. · Antimicrobial Agents and Chemotherapy · 3
PDF
Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda
2023 · Denis Omali, Allan Buzibye, et al. · African Journal of Laboratory Medicine · 3
PDF
Therapeutic drug monitoring for antimicrobial agents for people living with HIV (TAP)
2024 · Christine Sekaggya-Wiltshire, Eva Agnes Laker Odongpiny, et al. · Wellcome Open Research · 2
Works count: 52
Citation count: 555
H-index: 11
I10-index: 15
Year
Topic
Type